Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

RAHWAY, N.J.--(BUSINESS WIRE) March 19, 2024 -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational,...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials